Bear
if there are some patients in BOM on sglt2 inhibitors it might be interesting to see if those also on 208 show any synergies in a sub group analysis ? IF they do then perhaps there would be good rational for combination with sglt2i’s? Has the Company filed any Patents in this space ?
Thanks in advance !